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Abstract
Background: Ovarian cancer is the leading cause of death among women with gynecologic malignancies in the
United States. Advanced ovarian cancers are difficult to cure with the current available chemotherapy, which has
many associated systemic side effects. Doxorubicin is one such chemotherapeutic agent that can cause
cardiotoxicity. Novel methods of delivering chemotherapy without significant side effects are therefore of critical
need.
Methods: In the current study, we generated an irradiated tumor cell-based drug delivery system which uses
irradiated tumor cells loaded with the chemotherapeutic drug, doxorubicin.
Results: We showed that incubation of murine ovarian cancer cells (MOSEC) with doxorubicin led to the
intracellular uptake of the drug (MOSEC-dox cells) and the eventual death of the tumor cell. We then showed that
doxorubicin loaded MOSEC-dox cells were able to deliver doxorubicin to MOSEC cells in vivo. Further
characterization of the doxorubicin transfer revealed the involvement of cell contact. The irradiated form of the
MOSEC-dox cells were capable of treating luciferase-expressing MOSEC tumor cells (MOSEC/luc) in C57BL/6 mice as
well as in athymic nude mice resulting in improved survival compared to the non drug-loaded irradiated MOSEC
cells. Furthermore, we showed that irradiated MOSEC-dox cells was more effective compared to an equivalent dose
of doxorubicin in treating MOSEC/luc tumor-bearing mice.
Conclusions: Thus, the employment of drug-loaded irradiated tumor cells represents a potentially innovative
approach for the delivery of chemotherapeutic drugs for the control of ovarian tumors.
Introduction
Ovarian cancer is the leading cause of death among
women with gynecologic malignancies and is the eighth
most common cancer in the United States [1,2]. Most
patients who are diagnosed with ovarian cancer are
detected at an advanced stage (III/IV), often presenting
with complications associated with intraperitoneal
metastasis. Unfortunately, less than half of the women
diagnosed with ovarian cancer survive 5 year post-diag-
nosis [1,3]. Current chemotherapies are useful in the
control of advanced stages of ovarian cancer but have
many toxic side effects [4-6]. Thus, there is a critical
need for alternative approaches to administer
chemotherapeutic agents to control advanced stages of
ovarian cancer without serious side effects.
Doxorubicin, which is part of the anthracyline family,
has been successfully applied to treat a variety of tumors
including ovarian cancer (for review see [7]). While dox-
orubicin is more effective than its structural precursor,
daunorubicin, the major side effects of the drugs are
similar. Studies have shown that the toxicity of doxoru-
bicin can lead to chronic cardiomyopathy [8-10]. Thus,
some attempts have been made to diminish the toxicity
of doxorubicin. One currently administered form of
doxorubicin is DOXIL®, whereby doxorubicin is encap-
sulated by lipids to prolong the circulation of the drug
in the bloodstream [11]. Although the liposome protects
some cells from doxorubicin, they can reach systemic
circulation and the drug can still reach heart tissue to
cause damage.
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administration of doxorubicin delivered by irradiated
tumor cells may reduce the dose required to treat mur-
ine ovarian cancer cells and decrease the systemic circu-
lation of doxorubicin. We showed that preparation of
murine ovarian cancer cells (MOSEC) with doxorubicin
led to the intracellular uptake of the drug (MOSEC-dox
cells). We then showed that doxorubicin loaded
MOSEC-dox cells were able to deliver doxorubicin to
MOSEC cells in vivo. Thus, local delivery of chemother-
apeutic drugs by tumor may represent a potentially
innovative approach for the control of ovarian tumors.
Materials and methods
Mice
Female C57BL/6 and athymic nude mice (6-8 wks) were
acquired from the National Cancer Institute (Frederick,
MD). All animals were maintained under specific patho-
gen-free conditions, and all procedures were done
according to approved protocols and in accordance with
recommendations for the proper use and care of labora-
tory animals.
Cell lines and reagents
The HPV-16 E7-expressing murine tumor model, TC-1,
has been described previously [12]. In brief, HPV-16 E6,
E7, and the ras oncogene were used to transform pri-
mary C57BL/6 mice lung epithelial cells to generate the
TC-1 cell line. The MOSEC cell line was generated as
described previously [13]. The MOSEC cell line was ori-
ginally derived from murine ovarian surface epithelial
cells [13]. MOSEC-luciferase (MOSEC/luc) cells were
generated as described previously [14]. MOSEC cells
were transduced with a retrovirus containing luciferase.
In order to generate a retrovirus containing luciferase, a
pLuci-thy1.1 construct expressing both luciferase and
thy1.1 was made. Firefly luciferase was amplified by PCR
from pGL3-basic (Promega) using the 5’ primer CGGA-
GATC TATGGAAGACGCCAAAAAC and the 3’ pri-
mer CGGGTTAACTTACACGGCGATCTTTCC. The
amplified luciferase cDNA was inserted into the BglII
and HpaI sites of the bicistronic vector pMIG-thy1.1.
Both luciferase and thy1.1 cDNA are under the control
of a single promoter element and separated by an inter-
nal ribosomal entry site (IRES). The pLuci-thy1.1 was
transfected into Phoenix packaging cell line and the vir-
ion-containing supernatant was collected 48 h after
transfection. The supernatant was immediately treated
using a 0.45-mm cellulose acetate syringe filter (Nal-
gene, Rochester, NY, USA) and used to infect MOSEC
cells in the presence of 8 mg/ml Polybrene (Sigma, St
Louis, MO, USA). MOSEC/luc cells were sorted using
preparative flow cytometry of stained cells with Thy1.1
antibody (BD, Franklin Lakes, NJ, USA). MOSEC-GFP
cells were generated with a GFP-expressing lentivirus.
Briefly, the lentiviral vector pCDH1-EF1-GFP was
transfected into a Phoenix packaging cell line using lipo-
fectamine (Invitrogen, Carlsbad, CA, USA) and the vir-
ion-containing supernatant was collected 48 hours after
transfection. The supernatant was then filtered through
a 0.45 mm cellulose acetate syringe filter (Nalgene,
Rochester, NY, USA) and used to infect MOSEC cells in
the presence of 8 mg/ml Polybrene (Sigma-Aldrich, St
Louis, MO, USA). Transduced cells were isolated using
preparative flow cytometry with GFP signal. The growth
rate of all transduced cell lines was comparable with
those of the parental, non-transduced cell lines (data
not shown). Doxorubicin-HCL (D1515, Sigma-Aldrich,
St Louis, MO, USA) was reconstituted with 0.9% NaCl
normal saline and kept at 4°C for up to three weeks.
Determination of drug concentration inside doxorubicin-
treated cells
MOSEC cells (1 × 10
6/ml) were cultured with complete
media in the presence of different concentrations of
doxorubicin (specifically 1, 10, 50, 100 μg/ml) for 2
hours at 37°C. The cells were then centrifuged at 10,000
rpm for 2 mins and the supernatant aspirated. The
intracellular drug concentration was then determined
within the remaining cell pellets. The cell pellets were
lysed with protein extraction buffer (Pierce, Rockford,
IL) and a 1:1 volume of DMSO was added. The concen-
tration of drug was determined using a spectrophot-
ometer at a 470 nm wavelength. Standard solutions of
doxorubicin were made with media or extraction buffer
with DMSO and used to generate a standard curve. Lin-
ear regression analysis was performed to generate the
regression equation: y = 0.1607x -0.2143 with R
2 =
0.9102.
Drug uptake, viability and proliferation of cells
MOSEC and MOSEC/luc cells (1 × 10
6/ml) were cul-
tured in the presence of indicated doses of doxorubicin
(specifically, 0.01, 0.1, 1, 10, 50, 100 μg/ml) at 37°C for 2
hours. Analysis was performed on a BD FACScan with
CellQuest software (BD Biosciences Immunocytometry
Systems, Mountain View, CA). After 2 hours of incuba-
tion with the drug, 5 × 10
4 cells/well of doxorubicin-
treated MOSEC/luc cells were placed into 96-well plates
with complete medium. D-Luciferin (potassium salt;
Xenogen/Caliper Life Sciences, Alameda, CA) at a con-
centration of 150 μg/ml was added to each well 7-8
minutes before imaging at 24 hrs. The imaging time was
30 seconds/plate. A MTT assay was performed with
doxorubicin-treated MOSEC cells at 24 hours. The cells
were then divided into 96-well plates. The MTT solu-
tion (30 μlo fa5m g / m ls o l u t i o n )w a sa d d e dt o
the drug treated cancer cells and incubated for 4 hours.
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under vigorous shaking for 30 minutes which was fol-
lowed by detection of absorption at OD 570 nm using a
microplate reader (Molecular Probes, Invitrogen,
Eugene, OR).
Drug transfer in vitro and in vivo
MOSEC cells pre-treated with doxorubicin (100 μg/ml)
were mixed with MOSEC-GFP cells (5 × 10
5/well in 24-
well plates) according to the indicated ratios (5 × 10
3
(100:1), 1 × 10
4 (50:1), 2 × 10
4 (25:1), or 5 × 10
4 (10:1)/
well). After 24 hours, all the cells were collected and ana-
lyzed by flow cytometry. In order to confirm the necessity
of cell to cell contact in the transfer of the drug, MOSEC-
GFP cells (5 × 10
5/well in 24-well plates) were cultured in
the bottom well of transwell plates (Corning Costar,
Acton, MA) and MOSEC cells (5 × 10
4/well in 24-well
plates) pre-treated with doxorubicin (100 μg/ml) were
cultured in the upper chamber. After 24 hours, all of the
cells in the bottom well were collected and analyzed by
flow cytometry. For detecting transfer of drug in vivo,
female C57BL/6 mice were inoculated with MOSEC-GFP
(1 × 10
6/mouse) via the intraperitoneal route. After 24
hours, 2 × 10
4 (50:1) or 1 × 10
5 (10:1) MOSEC cells pre-
treated with doxorubicin (100 μg/ml, 2 hrs) were injected
into MOSEC-GFP tumor bearing mice. MOSEC-GFP
cells or MOSEC-dox cells alone (1 × 10
6 /mouse) were
injected into mice as controls. 24 hours after injecting
the drug treated cells, mice from all groups were sacri-
ficed with CO2 inhalation. Sterile PBS (10 ml) was
injected into the peritoneum of each mouse to obtain
peritoneal cells. Peritoneal cells (1 × 10
6 /mouse) were
then analyzed by flow cytometry.
Characterization of tumor cell death by drug-treated
tumor cells in vitro
MOSEC cells treated with a high dose (100 ug/ml) of
doxorubicin were co-cultured with MOSEC/luc cells (5
×1 0
4/well in 24-well plates) at different ratios (5 × 10
2
(100:1), 1 × 10
3 (50:1), 2 × 10
3 (25:1), or 5 × 10
3 (10:1)/
well). D-Luciferin (150 μg/ml) was added at different
time points (just after mixing, on day1, and on day 2)
and incubated for 7-8 min. An integration time of 30
seconds was used for luminescence image acquisition.
Data was obtained on day 2.
Characterization of anti-tumor effects by drug-loaded
tumor cells in C57BL/6 mice
Naïve female C57BL/6 mice were inoculated intraperito-
neally with 5 × 10
5 live MOSEC/luc cells per mouse.
On day 4 after tumor inoculation, tumor bearing mice
were injected with low (2 × 10
5/mouse) or high (2 ×
10
6/mouse) numbers of drug-treated, irradiated MOSEC
cells. Tumor-bearing mice were also injected with
2×1 0
5 irradiated MOSEC cells as a control. For drug-
treated, irradiated tumor cells, MOSEC cells were incu-
bated for 2 hours with 100 μg/ml of doxorubicin and
then subjected to 100,000 cGy/min for 10 minutes.
Tumor growth was assessed with luminescence image
acquisition on day 0 after treatment with drug treated
cells and, subsequently, on a weekly basis. The mice
were injected with 0.2 ml of 15 mg/ml D-luciferin.
Detection of luminescence activity indicating relative
tumor development was then performed using a Xeno-
gen IVIS 200 Imaging System.
Characterization of anti-tumor effects of drug-loaded
tumor cells in nude mice
A t h y m i cn u d em i c e( B 6b a c k g r o u n d )w e r ei n o c u l a t e d
intraperitoneally with 2.5 × 10
5 live MOSEC/luc cells
per mouse. On day 4, tumor bearing mice from each
group (5mice/group) were treated with irradiated
MOSEC cells (2 × 10
6/mouse) treated either with low
(10 μg/ml) or high (100 μg/ml) doses of doxorubicin.
Tumor growth was monitored on a weekly basis from
the day of MOSEC/luc tumor challenge using the biolu-
minescence imaging method mentioned above.
Comparison of the different treatment regimens
The concentration of drug inside the doxorubicin-
treated MOSEC cells was determined as described.
Naïve female C57BL/6 mice were challenged intaperito-
neally with 5 × 10
5 live MOSEC/luc cells per mouse.
O nd a y4 ,t u m o rb e a r i n gm i c ew e r ei n j e c t e dw i t h0 . 5
mg/kg (10 μg/mouse) of doxorubicin. To compare the
effects of treatment on tumors, drug-loaded irradiated
MOSEC cells (2 × 10
6/mouse, 100 μg/ml for 2 hrs) were
injected into tumor-bearing mice. Tumor growth was
monitored with luminescence activity on a weekly basis
from the day of MOSEC/luc cells challenge.
Statistical analysis
All data expressed as mean ± SD are representative of at
least two different experiments. Comparisons between
individual data points were made using a Student’s t
test. Differences in survival between experimental
groups were analyzed using the Kaplan-Meier approach.
The statistical significance of group differences will be
assessed using the log-rank test.
Results
Doxorubicin is taken up by MOSEC tumor cells leading to
tumor cell death
To characterize whether doxorubicin can be taken up by
tumor cells and lead to tumor cell death, we performed
various in vitro experiments using MOSEC and lucifer-
ase-expressing MOSEC (MOSEC/luc) tumor cells. Pools
of MOSEC and MOSEC/luc cells (1 × 10
6)w e r e
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Since an intrinsic characteristic of doxorubicin is auto-
fluoresence, after 2 hours of incubation with the drug,
the doxorubicin-treated MOSEC cells were subjected to
flow cytometry analysis. As shown in Figure 1A, histo-
grams of the doxorubicin-treated cell populations
demonstrated increased shift with increasing concentra-
tions of administered drug. We then checked the
amount of doxorubicin taken up by the MOSEC tumor
cells. After 2 hours of incubation with the drug, pools of
differing concentrations of doxorubicin -treated MOSEC
cells were collected and spun down to form cell pellets.
Protein-extraction buffer was added to lyse the cells and
release the intracellular doxorubicin and the amount of
drug inside the different cell pools was determined by a
standard curve using spectrophotometry analysis. We
f o u n dt h a tt h ea m o u n to fi n t r acellular doxorubicin for
each cell population increased with increasing concen-
trations of doxorubicin placed in the media, as shown in
Figure 1B. The rest of the drug remains in the solution.
To check the effects of doxorubicin on the viability of
MOSEC cells, the tumor cells were incubated with dox-
orubicin for 24 hours. We then performed MTT assays
to determine the viability of tumor cells after exposure
to doxorubicin. Figure 1C illustrates that with increasing
concentrations of doxorubicin, the numbers of viable
Figure 1 Characterization of doxorubicin treatment of tumor cells. MOSEC or MOSEC/luc tumor cells (1 × 10
6)w e r ec u l t u r e di nt h e
presence of different doses of doxorubicin: 0, 0.01, 0.1, 1,10, 50, 100 μg/ml. Flow cytometry was performed on doxorubicin-treated MOSEC cells
(MOSEC-dox) at 2 hrs of incubation. (A) Flow cytometry showing uptake of doxorubicin at each concentration by the MOSEC tumor cells.
Another pool of MOSEC cells incubated for 2 hrs with doxorubicin were spun to form cell-pellets, which were lysed with protein-extraction
buffer and added to DMSO. The amount of doxorubicin in the cell lysate solution was determined using spectrophotometry along with
generating a standard curve. (B) Bar graph superimposed under standard curve showing the amount of doxorubicin inside the MOSEC cells for
each concentration after extraction from cell lysates. The numbers above each bar indicate μg of doxorubicin per 1 × 10
6 cells. The left y-axis
indicates optical density reading at 470 nm; the right y-axis indicates micrograms of doxorubicin used to generate the standard curve. A pool of
MOSEC tumor cells was incubated with doxorubicin for 24 hrs and an MTT assay was then performed. (C) Representative bar graph from the
MTT data showing the viability of MOSEC cells after incubation with different concentrations of doxorubicin. MOSEC/luc tumor cells which were
incubated with doxorubicin for 24 hrs were imaged using bioluminescence IVIS systems. (D) Luminescence image showing luciferase activity in
viable MOSEC/luc cells. The numbers at the top indicate 3 identical trials of the same experiment. The bar graph depicts the kinetic expression
of luciferase in MOSEC/luc cells incubated with different amounts of doxorubicin.
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resulting in decreasing OD values. We also checked the
effects of doxorubicin on MOSEC/luc cells. After 24
hours of incubation, luciferin was added to doxorubicin-
treated MOSEC/luc cells followed by bioluminesence
imaging. As shown in Figure 1D, the luciferase activity
in viable MOSEC/luc cells decreased with increasing
concentrations of doxorubicin. Thus, our data suggests
that incubation of doxorubicin with MOSEC and
MOSEC/luc tumor cells leads to intracellular drug
uptake by the tumor cells, subsequently leading to cell
death. Furthermore, the degree of tumor cell death
induced by the drug increases with increasing concen-
tration of doxorubicin.
Transfer of doxorubicin from doxorubicin-loaded MOSEC
cells to untreated MOSEC cells (MOSEC-GFP) is mediated
through cells being in close vicinity of each other
One of the serious side effects of doxorubicin as a che-
motherapeutic agent is cardiotoxicity. Therefore, tar-
geted delivery of the chemotherapeutic drug to tumor
cells can potentially reduce the dose required for the
treatment and the systemic toxicity of the drug. In order
to test whether the doxorubicin in drug-loaded MOSEC
tumor cells could be transferred to other MOSEC
tumor cells, we performed flow cytometry experiments.
We found a certain number of MOSEC cells expressed
GFP and demonstrated red fluorescence of doxorubicin.
Figure 2A shows that the percentages of the double
positive cells from the total collected cells increased
with increasing ratios of added MOSEC-dox cells. This
suggests that doxorubicin was transferred from the
MOSEC-dox cells to the MOSEC-GFP cells. To deter-
mine if the drug transfer requires the cells to be contact
or in close vicinity of each other, we performed another
co-culture experiment utilizing a transwell system to
physically separate the cells during incubation. MOSEC-
GFP cells were plated in the bottom well and MOSEC-
dox cells were added to upper well. After 24 hours, we
evaluated the percentage of cells collected from the bot-
t o mw e l lo ft h et r a n s w e l ls y s t e mt h a ts h o w e dp r e s e n c e
of GFP and red fluorescent doxorubicin. We found that
a significantly lower percentage of cells collected from
the transwell showed presence of GFP and doxorubicin,
Figure 2 Flow cytometry analysis of MOSEC-GFP tumor cells incubated with MOSEC-dox cells mixed together or separated by a
transwell membrane. MOSEC cells incubated for 2 hrs in with doxorubicin (MOSEC-dox) at a concentration of 100 μg/ml were added to
MOSEC-GFP cells (5 × 10
5/well) in various amounts according to the indicated ratios. Another pool of MOSEC-dox cells (5 × 10
4) were added to
the upper plate of a transwell system with 5 × 10
5 MOSEC-GFP cells in the bottom plate. A transwell system in which the MOSEC-dox cells were
mixed together with MOSEC-GFP cells was used as a control. At 24 hrs of culture, the cells from the mixtures and from the bottom plate of the
transwell system were collected and analyzed for presence of GFP and doxorubicin using flow cytometry. Representative figures from the flow
cytometry data of (A) the different mixtures of MOSEC-GFP cells incubated with differing amounts MOSEC-dox cells and (B) bottom well
containing MOSEC-GFP cells of the transwell system, with data from the control mixture to the right. The numbers in the upper right hand
corner show the percentage of total collected cells that indicate presence of GFP and doxorubicin.
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control. These results support that cell-to-cell contact
or presence of cells in close vicinity of each other is
required for doxorubicin drug transfer from MOSEC-
dox cells to MOSEC-GFP cells.
We also performed the same in vitro experiments using
TC-1 and TC-1/luc cells. In the TC-1 cell line, we found
similar results to what we found in the MOSEC cell line.
TC-1 cells took up doxorubicin after 2 hours of incubation
and were killed after 24 hours (Figure 3). Furthermore, we
found that transfer of doxorubicin from TC-1-dox cells to
TC-1/luc cells required cell-to cell contact or presence of
cells in close vicinity of each other (Figure 4).
MOSEC-luc cells incubated with MOSEC-dox cells are
killed via transfer of doxorubicin
In order to determine whether the transfer of doxorubi-
cin would have a cytotoxic effect on target cells, we
performed in vitro tumor killing assays using luciferase-
expressing MOSEC tumor cells (MOSEC/luc). MOSEC-
luc cells were plated in 24-well plates and increasing
amounts of MOSEC-dox cells were added according to
fixed ratios. We found that MOSEC/luc cells were killed
after incubation with MOSEC-dox cells through the
direct transfer of doxorubicin. As shown in Figure 5A,
the luminescent intensity in the MOSEC/luc cells
decreases with increasing numbers of added MOSEC-dox
cells. The bioluminescence is an indirect measure of via-
bility of the tumor cells that can exhibit luciferase activ-
ity. The bar graph in Figure 5B illustrates the decreasing
levels of luminescent intensity as the numbers of
MOSEC-dox cells increase. Thus, our data suggests that
after 48 hours of incubation, doxorubicin-treated
MOSEC cells can cause cell death among MOSEC/luc
cells. Furthermore, higher numbers of MOSEC-dox cells
incur greater levels of tumor cell killing.
Figure 3 Characterization of doxorubicin-treated TC1 cells. TC1 or TC1/luc tumor cells (1 × 10
6) were cultured in the presence of different
doses of doxorubicin: 0, 0.01, 0.1, 1, 10, 50, 100 μg/ml. Flow cytometry was performed on doxorubicin-treated TC1 cells at 2 hrs of incubation.
An MTT assay was performed with another pool of TC1 tumor cells incubated for 24 hrs with doxorubicin. Bioluminescence imaging was done
with TC1/luc tumor cells incubated with doxorubicin for 24 hrs after adding luciferin. (A) Flow cytometry showing uptake of doxorubicin at each
concentration by the TC1 tumor cells. (B) Representative bar graph from the MTT data showing the viability of TC1 cells after treatment with
different concentrations of doxorubicin. (C) Bioluminescence image showing luciferase activity in TC-1 cells remaining after incubation with
doxorubicin. (D) Bar graph depicting the kinetic expression of luciferase in TC-1 cells incubated with different amounts of doxorubicin.
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by a transwell membrane. TC1 cells incubated for 2 hrs in the presence of doxorubicin (100 μg/ml) were added to TC1-GFP cells (7 × 10
5/
well) in various amounts according to ratios indicated. Doxorubicin (10 or 100 μg/ml)-treated TC1 cells (7 × 10
5) were also added to the upper
plate of a transwell system with the TC1-GFP cells (7 × 10
4) in the bottom plate. A control for the transwell experiment in which the
doxorubicin-treated TC1 cells were again mixed with TC1-GFP cells was done. At 24 hrs of culture, the cells from the mixture and from the
bottom plate of the transwell system were collected and analyzed using flow cytometery. (A and B) Representative flow cytometery data of (A)
TC1-GFP cells mixed with differing amounts of doxorubicin-treated TC1 cells and (B) TC1-GFP cells from the bottom well of the transwell system,
the control data to the right. The numbers in the upper right hand corner of each dot plot show the percentage of cells that contain GFP and
doxorubicin.
Figure 5 In vitro tumor killing assay. MOSEC/luc tumor cells (5 × 10
4/well) were plated in 24-well plates. Different amounts of MOSEC-dox(100
μg/ml) doxorubicin were added to the MOSEC/luc cells according to the indicated ratios. After 48 hrs, luciferin was added to the cells 7-8 min
before bioluminescence images were taken of the cells. (A) Representative bioluminescent image of the tumor cells at 2 days of incubation. The
numbers at the top indicate 3 identical trials of the same experiment. (B) Bar graph depicting the measured expression of luciferase in the
viable MOSEC/luc tumor cells. *p < 0.01.
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MOSEC-GFP cells in vivo
In order to determine whether the transfer of doxorubi-
cin by drug-loaded tumor cells seen in cell culture
would also occur in vivo, we inoculated C57BL/6 mice
with MOSEC-GFP tumor cells intraperitoneally. We
then injected the mice one day later with different
amounts of MOSEC-dox cells according to fixed ratios.
24 hours later, the intraperitoneal cells were collected
from the peritoneal cavity and analyzed using flow cyto-
metry for the presence of intracellular doxorubicin and
GFP. We found that transfer of doxorubicin between
cells also occurred in vivo. As shown in Figure 6, a sub-
set of collected intraperitoneal cells both expressed GFP
and showed red fluorescence by doxorubicin. The
percentages of cells that contained both doxorubicin
and GFP increased with higher numbers of added
MOSEC-dox cells. Overall, the percentages of total col-
lected cells that showed presence of doxorubicin and
GFP from the in vivo experiment were lower than the
percentages from the in vitro experiments. This can be
explained by the number of endogenous, non-cancerous,
intraperitoneal cells collected and evaluated as part of
the total number of intraperitoneal cells assayed. Thus,
our data suggests that transfer of doxorubicin observed
in vitro between MOSEC-dox and MOSEC-GFP cells
can also occur in vivo.
Administration of irradiated MOSEC-dox tumor cells to
MOSEC/luc tumor-bearing mice leads to decreased tumor
burden
We examined the doxorubicin-treated MOSEC cells as a
modality of treatment for MOSEC tumors. C57BL/6
mice were inoculated with MOSEC/luc cells. After 4
days, groups of tumor-bearing mice were administered
either different doses of irradiated MOSEC-dox cells.
One group of tumor-bearing mice administered irra-
diated MOSEC cells or no treatment were used as con-
trols. Luminescence activity has been shown to correlate
well with tumor load using luciferase-expressing tumor
cells in previous studies by us and other groups, [15-18].
Thus, we believe luciferase activity can be used as a sui-
table indicator of tumor load in tumor-bearing mice. As
s h o w ni nF i g u r e7 A ,t h es i z eo ft u m o r sa si n d i c a t e db y
the levels of luciferase activity were decreased in tumor-
bearing mice treated with higher number of irradiated
MOSEC-dox cells. The luciferase activity was quantified
as illustrated in Figure 7B. This indicates that the
administration of MOSEC-dox cells to MOSEC/luc
tumor-bearing mice led to significantly decreased tumor
growth. Tumor-bearing mice treated with MOSEC-dox
cells/mouse also showed improved survival compared to
the other groups (Figure 7C). Thus, our data suggests
that higher numbers of irradiated MOSEC-dox cells can
be used to treat MOSEC/luc tumor bearing C57BL/6
mice and can improve survival.
Administration of irradiated, pre-treated MOSEC cells with
high levels of doxorubicin to MOSEC/luc tumor-bearing
athymic nude mice leads to decreased tumor burden
We also examined irradiated MOSEC-dox cell vaccina-
tion as treatment in athymic nude tumor-bearing mice,
which would allow us to characterize the antitumor effect
without involvement of T cell-mediated immune
responses. Mice were inoculated with MOSEC/luc cells.
After four days, groups of tumor-bearing nude mice were
administered irradiated MOSEC cells pre-treated with
doxorubicin. We found that administration of irradiated
MOSEC-dox cells that were pre-treated with 100 μg/ml
of doxorubicin to MOSEC/luc tumor-bearing mice led to
significantly decreased tumor growth. Administration of
Figure 6 Flow cytometry analysis of peritoneal cells after
intraperitoneal injections of MOSEC-GFP and MOSEC-dox cells.
MOSEC-GFP tumor cells (1 × 10
6/mouse) were intraperitoneally
injected into groups of C57BL/6 mice, followed 1 day later by
intraperitoneal injection of MOSEC-dox cells (2 × 10
4 or 1 × 10
5/
mouse). As controls, C57BL/6 mice were injected with only MOSEC-
GFP or MOSEC-dox cells or no cells. One day after the last injection,
all mice were sacrificed. Cells were collected from the
intraperitoneal cavity by peritoneal wash (PW) and analyzed using
flow cytometry specific for GFP and doxorubicin. Representative
figures from the flow cytometry data showing migration of
peritoneal wash cells collected from the mice injected with MOSEC-
GFP and MOSEC-dox cells.
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10 μg/ml of doxorubicin had little to no effect on tumor
growth. As shown in Figure 8A, the sizes of tumors as
indicated by the levels of luciferase activity are decreased
in tumor-bearing mice treated with the irradiated
MOSEC-dox cells incubated with the higher concentra-
tion of doxorubicin. The luciferase activity was quantified
as illustrated in Figure 8B. Furthermore, tumor-bearing
nude mice treated with the irradiated MOSEC-dox(100
μg/ml) cells showed enhanced survival compared to the
other mice groups (Figure 8C). Thus, our data suggests
that irradiated MOSEC-dox cells that have been incu-
bated with a high concentration of doxorubicin can be
used to treat MOSEC/luc tumors in athymic nude mice,
leading to significantly reduced tumor burden and pro-
longed survival.
Irradiated MOSEC-dox tumor cells are more effective than
doxorubicin alone as treatment for MOSEC/luc tumors
We compared doxorubicin-treated MOSEC cells to dox-
orubicin alone as treatment for MOSEC tumors. C57BL/
6 mice were inoculated with MOSEC/luc cells. After 4
days, one group of tumor-bearing mice was administered
irradiated MOSEC-dox cells pre-treated with 100 μg/ml
of doxorubicin. Based on Figure 1B, we determined the
concentration of intracellular doxorubicin in the MOSEC
cells pre-treated with 100 μg/ml of doxorubicin. For
comparison, another group of tumor-bearing mice was
administered doxorubicin alone. We found that adminis-
tration of irradiated MOSEC-dox cells to MOSEC/luc
tumor-bearing mice led to decreased tumor growth;
whereas, administration of 10 μg of doxorubicin alone to
MOSEC/luc tumor-bearing mice led to little or no anti-
tumor effects. As shown in Figure 9A, the size of tumors
as indicated by the levels of luciferase activity are
decreased in tumor-bearing mice treated with the irra-
diated MOSEC-dox cells. Treatment of tumor-bearing
mice with a comparable level of doxorubicin did not lead
to a significant decrease in tumor sizes. The luciferase
activity was quantified as illustrated in Figure 9B.
Furthermore, tumor-bearing mice treated with irradiated
MOSEC-dox cells showed enhanced survival compared
to the other groups (Figure 9C). Thus, our data suggests
that delivery of small amounts of drug via irradiated
tumor cells containing doxorubicin is more effective in
treating MOSEC/luc tumor-bearing mice than direct
treatment with the drug alone.
Discussion
In the current study, we generated a chemotherapeutic
drug delivery system using irradiated MOSEC tumor
cells which was capable of delivering the drug to other
Figure 7 In vivo tumor treatment experiment. C57BL/6 mice were inoculated with 5 × 10
5/mouse of MOSEC/luc tumor cells. Four days later,
MOSEC/luc tumor-bearing mice were treated with a low (2 × 10
5/mouse) or high (2 × 10
6/mouse) numbers of irradiated MOSEC-dox(100 μg/
ml) tumor cells. As controls, groups of MOSEC/luc tumor-bearing mice were treated with irradiated MOSEC cells (2 × 10
5/mouse) or left without
treatment (naïve). Survival analysis was also performed of the different groups of mice. (A) Representative bioluminescence images of MOSEC/luc
tumor-bearing mice treated with the different numbers of doxorubicin-treated MOSEC tumor cells. (B) Line graph illustrating the measured
values of luminescent intensity in the different groups of mice. (C) Kaplan-Meier survival analysis of MOSEC/luc tumor-bearing mice treated with
low and high numbers of doxorubicin-treated MOSEC cells compared to the control groups.
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potent therapeutic antitumor effects. Using the unique
property of doxorubicin’s red auto-fluoresence, we
found that incubation of MOSEC cells with doxorubicin
led to the intracellular uptake of the drug and the even-
tual death of the tumor cells. We also found that drug-
loaded tumor cells were capable of transferring the drug
to other non-drug-loaded tumor cells in close vicinity.
In addition, we found that the use of irradiated
MOSEC-dox cells to deliver doxorubicin is more effec-
tive in treating MOSEC/luc tumors than administration
of a comparable dose of doxorubicin alone. Thus, our
study suggests that local delivery of chemotherapeutic
drugs by tumor cells may require significantly less
amount of drug to control ovarian cancer. The success
of the current study warrants further exploration of
such a delivery approach using other chemotherapeutic
drugs for the treatment of cancers.
Our study shows that irradiated tumor cells loaded
with a chemotherapeutic drug can lead to the control of
MOSEC tumors. We have revealed that this delivery
system is capable of transferring doxorubicin to other
tumor cells in vitro and in vivo resulting in tumor cell
death. The mechanism of chemotherapeutic action of
doxorubicin on cancer cells is through DNA intercala-
tion and topoisomerase II enzyme inhibition [19].
Through these two actions, doxorubicin can disrupt cel-
lular processes involving DNA such as synthesis and
transcription, leading to cell death. Thus, we can reason
that the antitumor effects observed as a result of treat-
ment with irradiated MOSEC-dox tumor cells can be
partly attributed to doxorubicin-mediated tumor-cell
killing. Other contributing factors for the observed ther-
apeutic effects include chemotherapy-induced cell death
and subsequent antitumor activity based on activation of
the immune system. Our previous studies have shown
that tumor cells treated with chemotherapy can lead to
tumor cell death, resulting in activation of tumor-speci-
fic immunity [20-22].
The observed antitumor effects generated by doxoru-
bicin-loaded tumor cells m a ya l s ob ec o n t r i b u t e db y
tumor-specific immunity. Recent studies have shown
that anthracycline drugs including doxorubicin induce
the rapid, preapoptotic translocation of calreticulin
(CRT) to the cell surface and result in improved proces-
sing of tumor cells by dendritic cells [23]. Thus, the
expression of CRT on the surface of tumor cells
mediated by doxorubicin may play an important role in
the generation of anticancer immune responses. Thus,
doxorubicin-loaded tumor cells may generate antitumor
effects through doxorubicin-mediated killing as well as
tumor-specific immunity.
Figure 8 Characterization of the anti-tumor effects of MOSEC-dox tumor cells in nude mice. Athymic nude mice were inoculated with
2.5 × 10
5/mouse of MOSEC/luc tumor cells. Four days later, MOSEC/luc tumor-bearing mice were treated with 2 × 10
6/mouse of irradiated
MOSEC-dox(10 μg/ml or 100 μg/ml) tumor cells. A group of MOSEC/luc tumor-bearing nude mice without treatment was used as a control
(naïve). Survival analysis was also performed of the different groups of mice. (A) Representative bioluminescence images of different MOSEC-dox
treated mice compared to the control. (B) Line graph illustrating the kinetic expression of luciferase in the different MOSEC-dox treated mice
compared to the control. (C) Kaplan-Meier survival analysis of different MOSEC-dox treated mice compared to the control.
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feasibility for the use of this novel delivery system in
clinics. While this delivery system is used to deliver the
drug directly to tumor cells, it is possible that MOSEC-
dox cells may also deliver doxorubicin to healthy fibro-
blasts and other cells. This raises concerns for toxicity.
Nevertheless, we expect that normal cells such as fibro-
blasts would be less susceptible to the effects of the
drug as compared to tumor cells at the same concentra-
tion of drug delivered by MOSEC-dox. This is generally
true in the case of free form of doxorubicin. In addition,
intraperitoneal mode of delivery of irradiated tumor
cells loaded with drug would potentially have less sys-
temic toxicity compared to intravenous drug delivery.
The irradiation of drug-loaded tumor cells will further
alleviate concerns for growth of the drug-loaded tumor
cells following injection. Furthermore, the principle gen-
erated from the current study provides the rationale for
further exploration of alternative options for drug deliv-
ery such as controlled release biodegradable polymers
[24,25] or non neoplastic cells from patients such as
fibroblasts or PBMCs. It will be important to further
test whether these kinds of reagents will be able to
generate equivalent or better effects compared to the
current approach.
In summary, our study demonstrates that the employ-
ment of drug-loaded irradiated tumor cells represents a
potentially innovative approach for the delivery of che-
motherapeutic drugs for the control of ovarian tumors.
Further exploration in this area will create the opportu-
nity for the development of innovative chemotherapy
regimens for the control of ovarian cancer.
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